| Literature DB >> 35121640 |
Ida K Haugen1, David Felson2,3, Abhishek Abhishek4,5, Francis Berenbaum6,7, John James Edwards8, Gabriel Herrero Beaumont9, Merete Hermann-Eriksen10, Catherine L Hill11,12, Mariko Ishimori13, Helgi Jonsson14, Teemu Karjalainen15, Ying Ying Leung16, Emmanuel Maheu7, Christian D Mallen8, Rikke Helene Moe17, Roberta Ramonda18, Valentin Ritschl19,20, Tanja A Stamm19,20, Zoltan Szekanecz21, Florus J van der Giesen22, Marco J P F Ritt23, Ruth Wittoek24, Ingvild Kjeken17, Nina Osteras17, Lotte A van de Stadt22, Martin Englund25, Krysia S Dziedzic8, M Marshall8, Sita Bierma-Zeinstra26, Paul Hansen27, Elsie Greibrokk10, Wilma Smeets22, Margreet Kloppenburg22,28.
Abstract
OBJECTIVES: In Phase 1 of developing new hand osteoarthritis (OA) classification criteria, features associated with hand OA were identified in a population with hand complaints. Radiographic findings could better discriminate patients with hand OA and controls than clinical examination findings. The objective of Phase 2 was to achieve consensus on the features and their weights to be included in three radiographic criteria sets of overall hand OA, interphalangeal OA and thumb base OA.Entities:
Keywords: epidemiology; health care; osteoarthritis; outcome assessment
Mesh:
Year: 2022 PMID: 35121640 PMCID: PMC8819785 DOI: 10.1136/rmdopen-2021-002024
Source DB: PubMed Journal: RMD Open ISSN: 2056-5933
Figure 1Overview of the development of classification criteria sets for overall hand OA, interphalangeal OA and thumb base OA. IP, interphalangeal; OA, osteoarthritis.
Figure 2Example of a trade-off question from the 1000minds preferences survey. CMC1, first carpometacarpal; DIP, distal interphalangeal; IP1, first interphalangeal; OA, osteoarthritis; PIP, proximal interphalangeal.
Figure 3Ranking of the 25 patient vignettes from 1st (most likely) to 25th (least likely) based on the likelihood of their symptoms being due to hand OA. Each square or circle represents the rank of one expert. The blue line shows the mean rank across all experts. OA, osteoarthritis.
Criteria for overall hand OA with the mean weight assigned to each criterion (bolded numbers) and the categories within each criterion
| Criteria and categories | Mean weight 1* | Mean weight 2* |
| Age | ||
| 0 | 0 | |
| 5.9 | 8.1 | |
| 9.5 | 13.0 | |
|
|
| |
| Duration of symptoms in DIPs, PIPs, IP1 and thumb base joints | ||
| 0 | – | |
|
| ||
| Duration or morning stiffness in DIPs, PIPs, IP1 and thumb base joints | ||
| 0 | 0 | |
| 5.6 | 7.7 | |
|
|
| |
| Duration of stiffness after inactivity in DIPs, PIPs, IP1 and thumb base joints | ||
| 0 | – | |
| 2.5 | ||
|
| ||
| Number of DIPs, PIPs, IP1 and CMC1 joints with osteophytes | ||
| 0 | 0 | |
| 9.0 | 12.4 | |
| 15.9 | 21.8 | |
|
|
| |
| Number of DIPs, PIPs, IP1 and CMC1 joints with joint space narrowing | ||
| 0 | 0 | |
| 6.8 | 9.3 | |
| 11.0 | 15.1 | |
|
|
| |
| Radiographic OA (osteophytes or joint space narrowing) in at least 50% of the joints (DIPs, PIPs, IP1 and CMC1), in which the person has experienced pain, aching or stiffness on most days in the previous 6 weeks | ||
| 0 | 0 | |
|
|
| |
| Inflammatory biomarkers | ||
| 0 | – | |
| 3.4 | ||
|
| ||
*Weight 1: initial weights for the 8 criteria tested in the 1000minds survey.
†Weight 2: weights for the 5 criteria after removal of 3 criteria. The sum of the weights for each criterion’s most extreme category (bolded weights) across the criteria gives a total score of 100.
CMC1, first carpometacarpal; CRP, C reactive protein; DIP, distal interphalangeal; ESR, erythrocyte sedimentation rate; IP1, first interphalangeal; OA, osteoarthritis; PIP, proximal interphalangeal.
Figure 4Proportions of experts who would enrol the patient in a hypothetical clinical trial of a possible disease-modifying drug for patient vignettes arranged from the lowest to the highest probability of being classified as having hand OA based on the calculated total score from the Phase 2 criteria set. The white numbers in the blue bars represent the total scores (range: 0–100) based on the criteria set presented in table 1 (weight 2). DMOAD, disease-modifying osteoarthritis drug; OA, osteoarthritis.